Safety trial of heated factor VIII concentrate (8Y).

Confirmation of viral safety of dry heated factor VIII concentrate (8Y) prepared by Bio Products Laboratory (BPL): a report on behalf of U.K. Haemophilia Centre Directors.

Twenty-seven factor VIII deficient patients who had previously not been treated with blood or blood products were studied after infusion of a total of 24 batches of NHS factor VIII (8Y) concentrate produced by Bio-Products Laboratory, Elstree. Follow-up was carried out according to guidelines laid down by the International Society for Thrombosis and Haemostasis. Serial estimations of amino tran...

Molecular characterization of commercial porcine factor VIII concentrate.

Commercial porcine factor VIII concentrate (Hyate:C) is effective in treatment of patients with hemophilia A who have circulating antibodies to factor VIII. The molecular forms of factor VIII in the concentrate were identified and evaluated in light of the known properties of porcine and human factor VIII. The factor VIII in the concentrate was isolated by tandem chromatography on gelatin-Sepha...

Small Pool Heat-treated Intermediate Purity Factor Viii Concentrate

Comparison of factor VIII-related von Willebrand factor proteins prepared from human cryoprecipitate and factor VIII concentrate.

Both commercial factor VIII concentrate and cryoprecipitate have factor VIII coagulant activity and factor VIII antigen (VIIIR:Ag). but the concentrate lacks the von Willebrand activity (VIIIR:WF) found in the cryoprecipitate. In an effort to find a possible cause for this anomaly we compared the structures of VlllR:WF proteins responsible for the VllIR:Ag and VlllR:WF activities obtained from ...

von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.

BACKGROUND While plasma-derived concentrates containing large amounts of von Willebrand factor (VWF) are effective in treating von Willebrand disease (VWD), optimal dosing remains to be fully characterized. OBJECTIVES To determine the feasibility of dosing Haemate P VWF/factor VIII (FVIII) concentrate based on pharmacokinetics (PK) in the management of surgical subjects with VWD. METHODS VW...